{"filings":[{"id":722836,"accession_number":"0001213900-26-062155","cik":2075320,"company_name":"Polaryx Therapeutics, Inc.","ticker":"PLYX","form_type":"8-K","filed_at":"2026-05-28T20:31:45+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Polaryx closes $10M PIPE at ~$4.00/share to fund Phase 2 SOTERIA basket trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 2,502,696 common shares at avg $4.00/share for $10M gross proceeds to ~35 investors.","Largest stockholder MStone Partners Healthcare purchased 88,453 shares ($360k) in the offering.","Net proceeds will fund initiation of Phase 2 SOTERIA trial (CLN2, CLN3, Krabbe, Sandhoff) and extend cash runway through Q2 2027.","No resale registration statement will be filed; shares issued under Section 4(a)(2) and Regulation S exemption.","FDA Fast Track Designation already in place for all four planned LSD indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}